

November 26, 2003

**AMENDMENTS TO THE SPECIFICATION**

Please amend the specification pursuant to 37 C.F.R. 1.121 as follows:

Please replace the original Title of Invention on page 1, line 1 of the specification with the following amended Title of Invention:

-- **HUMAN CTLA-4 ANTIBODIES AND THEIR USES** --

Please replace the paragraph starting on page 5, line 8 with the following amended paragraph:

-- In a related aspect, the invention also provides a therapeutically-effective human sequence antibody that specifically binds to human CTLA-4. In some embodiments, the therapeutically-effective human sequence antibody binds to CTLA-4 on the cell surface of normal human T cells. In other embodiments, the T cell subpopulations marked by CD antigens CD4, CD8, CD25, and CD69 remain stable during and subsequent to the administration of the therapeutically-effective human sequence antibody. In other embodiments, the therapeutically-effective human sequence antibody binds CTLA-4 on the cell surface of normal human T cells. In other embodiments, the human sequence antibody is well-tolerated in a patient. ~~In a related embodiment,~~ --

Please delete the original Abstract of the Disclosure in its entirety and insert, in its place, the Substitute Abstract of the Disclosure attached hereto at **Tab 1**.

\* \* \* \* \*